Bao Chunhui

Comparative effect of electroacupuncture and moxibustion on the expression of substance P and vasoactive intestinal peptide in patients with irritable bowel syndrome.

OBJECTIVE To compare the impacts of electroacu puncture (EA) and moxibustion (Mox) on the prima ry gastrointestinal symptoms and the expressions of colonic mucosa-associated neuropeptide substance P (SP) and vasoactive intestinal peptide (VIP) in patients with either diarrhea-predominant or constipation-predominant irritable bowel syndrome (IBS-D and IBS-C, respectively). METHODS Eighty-five IBS patients were randomly allocated to the EA and Mox groups. Zusanli (ST 36) and Shangjuxu (ST 37) were selected as acupoints for electroacupuncture or warm moxibustion treatment once a day for 14 consecutive days. Before and after the treatment sessions, a Visual Analog Pain Scale and the Bristol Stool Form Scale were used to evaluate gastrointestinal symptoms. There were four dropout cases, leaving 81 participants (41 with IBS-D and 40 with IBS-C) who volunteered to undergo colonoscopy before and after the treatment sessions. During colonoscopy, sigmoid mucosa were collected to detect SP and VIP expression using immunohistochemistry assay. RESULTS Both EA and Mox treatments were effective at relieving abdominal pain in IBS-D and IBS-C patients. However, Mox was more effective at reducing diarrhea in IBS-D patients, whereas EA was more effective at improving constipation in IBS-C patients. EA and Mox treatments both down-regulated the abnormally increased SP and VIP expression in the colonic mucosa, with no significant difference shown between the two treatments. CONCLUSION Both EA and Mox treatments are effective at ameliorating gastrointestinal symptoms by reducing SP and VIP expression in the colonic mucosa of IBS patients.

Effect of warming moxibustion Tianshu (ST 25, bilateral) and Qihai (CV 6) for the treatment of diarrhea-dominant irritable bowel syndrome: a patient-blinded pilot trial with orthogonal design

Abstract Objective To investigate the effects of warming moxibustion Tianshu (ST 25, bilateral) and Qihai (CV 6) in patients with diarrhea-dominant irritable bowel syndrome (D-IBS) by assessing predominant factors, and determining the best factor combinations and their interactions. To identify the optimal quantity of warming moxibustion Tianshu (ST 25, bilateral) and Qihai (CV 6) to achieve optimal efficacy. Methods An L9 (3 4 ) orthogonal design was applied to 233 confirmed subjects based on the three most influential factors and the three most frequently used levels. Nine programs were designed. Subjects were assigned to four subgroups according to age and gender; each subject underwent one of the nine programs randomly. We selected Tianshu (ST 25, bilateral) and Qihai (CV 6). The scores of symptoms and the IBS Quality of Life (IBS-QOL) were evaluated after the final treatment. Results After treatment, clinical symptoms of all patients were significantly improved ( P = 0.001). Quality of life also improved significantly ( P P = 0.01). Duration was the dominating factor for quality of life ( P = 0.0001). The best combination for improving symptoms in 30–40-year-old male and female patients was two courses of 10 min each once a day, and for 41–50-year-old male and female patients it was three courses of 10 min (males) or 30 min (females) twice a day. The best combination for quality of life was three courses of 20 min once a day. No interaction was found between frequency and course, or frequency and duration. Conclusion Warming moxibustion Tianshu (ST 25, bilateral) and Qihai (CV 6) is a promising therapy for D-IBS. To acquire optimal efficacy, the three main factors (duration, frequency and treatment course) of the warming moxibustion should reach a specific quantity and be combined appropriately.